Annals of Oncology 14:1010-1011, 2003
© 2003 European Society for Medical Oncology
Original Paper |
ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of prostate cancer
Department of Oncology, University Hospital of Kuopio, Kuopio, Finland
| The first 10% of the full text of this article appears below. |
| Incidence |
|---|
- The age-standardized incidence of prostate cancer in the European Union is 65/100 000, and mortality 26/100 000 per year. It is the most common male cancer in Western Europe and the Nordic countries. The mean diagnostic age is 71 years. Latent sub-clinical prostate cancer is very common in men >80 years. Only 1 in 10 latent cancers will eventually become clinical cancers.
| Early diagnosis |
|---|
- Early diagnosis (screening)
. . . [Full Text of this Article]
| Staging |
|---|
| Treatment of localized prostate cancer (T14NXM0) |
|---|
| Treatment of metastatic prostate cancer |
|---|
| Follow-up |
|---|
| Note |
|---|
| Literature |
|---|
This article has been cited by other articles:
![]() |
H. Ludwig A Foundation for the future Ann. Onc., January 1, 2005; 16(1): 3 - 3. [Full Text] [PDF] |
||||
![]() |
E. K. Salminen, R. I. Portin, A. Koskinen, H. Helenius, and M. Nurmi Associations between Serum Testosterone Fall and Cognitive Function in Prostate Cancer Patients Clin. Cancer Res., November 15, 2004; 10(22): 7575 - 7582. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Ludwig European Society of Medical Oncology membership survey Ann. Onc., February 1, 2004; 15(2): 181 - 182. [Full Text] [PDF] |
||||

